Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

About this update from Immix Biopharma, Inc.

[{"type":"image","alt":"Immix Biopharma, Inc.","displaySize":"","headline":null,"caption":"Immix Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wOmQhF0jrEFCj3SbuTNPPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d","width":300,"height":93}},"lazy":false},{"type":"text","content":"- Oral presentation Sunday, December 7, at ASH 2025 -","length":53,"tagName":"p"},{"type":"text","content":"LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025.","length":468,"tagName":"p"},{"type":"text","content":"ASH 2025 Presentation Details – NXC-201","length":39,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:107.6px;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;","val":[{"type":"text","content":"Title","length":5,"tagName":"p","attribs":{}}]},{"style":"width:515.07px;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;","val":[{"type":"text","content":"“First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201”","length":135,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:107.67px;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;","val":[{"type":"text","content":"Presentation Date/Time (Eastern Time)","length":39,"tagName":"p","attribs":{}}]},{"style":"width:515.67px;border-right:solid black 1pt;border-bottom:solid black 1pt;","val":[{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Date: December 7, 2025","length":35,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Time: 5:45 PM - 6:00 PM ET","length":39...

More updates from Immix Biopharma, Inc.